Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

PDF  |  How to cite

Oncotarget. 2021; 12:2231-2231. https://doi.org/10.18632/oncotarget.28012

Metrics: PDF 1230 views  |   ?  

Joshua E. Allen1, C. Leah B. Kline2, Varun V. Prabhu1, Jessica Wagner2, Jo Ishizawa3, Neel Madhukar4, Avital Lev2, Marie Baumeister2, Lanlan Zhou2, Amriti Lulla2, Martin Stogniew1, Lee Schalop1, Cyril Benes5,6, Howard L. Kaufman7, Richard S. Pottorf8, B. Rao Nallaganchu8, Gary L. Olson8, Fahd Al-Mulla9, Madeleine Duvic3, Gen Sheng Wu10, David T. Dicker2, Mala K. Talekar11, Bora Lim3, Olivier Elemento4, Wolfgang Oster1, Joseph Bertino7, Keith Flaherty5,6, Michael L. Wang3, Gautam Borthakur3, Michael Andreeff3, Mark Stein7 and Wafik S. El-Deiry2

1 Oncoceutics, Inc., Philadelphia, PA, USA
2 Fox Chase Cancer Center, Philadelphia, PA, USA
3 University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 Weill Cornell Medicine, New York, NY, USA
6 Harvard Medical School, Boston, MA, USA
7 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
8 Provid Pharmaceuticals, Monmouth Junction, NJ, USA
9 Kuwait University Medical School, Kuwait
10 Karmanos Cancer Institute, Detroit, MI, USA
11 The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

Published: October 12, 2021

Copyright: © 2021 Allen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The COI statement has been updated. Please see the revised text below:


W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

Original article: Oncotarget. 2016; 7:74380–74392. DOI: https://doi.org/10.18632/oncotarget.11814

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28012